Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350))

Alex Friedlaender; Jarushka Naidoo; Giuseppe Luigi Banna; Giulio Metro; Patrick Forde; Alfredo Addeo

doi:10.1016/j.ctrv.2022.102358

Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350))

Alex Friedlaender, Jarushka Naidoo, Giuseppe Luigi Banna, Giulio Metro, Patrick Forde, Alfredo Addeo

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The authors regret that the captions given with Figs. 1–3 in the published article are incorrectly ordered. The correct figure captions with figures are given here. The authors would like to apologise for any inconvenience caused.

Original language	English (US)
Article number	102358
Journal	Cancer Treatment Reviews
Volume	104
DOIs	https://doi.org/10.1016/j.ctrv.2022.102358
State	Published - Mar 2022

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctrv.2022.102358

Fingerprint

Dive into the research topics of 'Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350))'. Together they form a unique fingerprint.

Cite this

Friedlaender, A., Naidoo, J., Luigi Banna, G., Metro, G., Forde, P., & Addeo, A. (2022). Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350)). Cancer Treatment Reviews, 104, Article 102358. https://doi.org/10.1016/j.ctrv.2022.102358

Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350)). / Friedlaender, Alex; Naidoo, Jarushka; Luigi Banna, Giuseppe et al.
In: Cancer Treatment Reviews, Vol. 104, 102358, 03.2022.

Research output: Contribution to journal › Comment/debate › peer-review

Friedlaender, A, Naidoo, J, Luigi Banna, G, Metro, G, Forde, P & Addeo, A 2022, 'Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350))', Cancer Treatment Reviews, vol. 104, 102358. https://doi.org/10.1016/j.ctrv.2022.102358

Friedlaender A, Naidoo J, Luigi Banna G, Metro G, Forde P, Addeo A. Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350)). Cancer Treatment Reviews. 2022 Mar;104:102358. doi: 10.1016/j.ctrv.2022.102358

@article{bfe9680e82af4aa28e3857e76345bf17,

title = "Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350))",

abstract = "The authors regret that the captions given with Figs. 1–3 in the published article are incorrectly ordered. The correct figure captions with figures are given here. The authors would like to apologise for any inconvenience caused.",

author = "Alex Friedlaender and Jarushka Naidoo and {Luigi Banna}, Giuseppe and Giulio Metro and Patrick Forde and Alfredo Addeo",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = mar,

doi = "10.1016/j.ctrv.2022.102358",

language = "English (US)",

volume = "104",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350))

AU - Friedlaender, Alex

AU - Naidoo, Jarushka

AU - Luigi Banna, Giuseppe

AU - Metro, Giulio

AU - Forde, Patrick

AU - Addeo, Alfredo

PY - 2022/3

Y1 - 2022/3

N2 - The authors regret that the captions given with Figs. 1–3 in the published article are incorrectly ordered. The correct figure captions with figures are given here. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that the captions given with Figs. 1–3 in the published article are incorrectly ordered. The correct figure captions with figures are given here. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85125128962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125128962&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2022.102358

DO - 10.1016/j.ctrv.2022.102358

M3 - Comment/debate

C2 - 35219091

AN - SCOPUS:85125128962

SN - 0305-7372

VL - 104

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

M1 - 102358

ER -

Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350))

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this